CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, announced today the opening of a new facility, including state-of-the-art Biosafety level 3 (BSL-3) laboratories, in Welwyn Garden City, UK. The BSL-3 laboratories will be dedicated to research, development and drug discovery alliance programmes based on the company’s proprietary in vitro models of viral liver infection, including Hepatitis B. The new facility will additionally comprise BSL-2 laboratories, an engineering laboratory and office space.
- Changing Times, Why Pharmacokinetics Matter in Drug Discovery 15th September 2021
- CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University 27th July 2021
- Lonza and CN Bio Announce Distribution Agreement 19th July 2021